FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM
FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM Basic information
- Product Name:
- FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM
- Synonyms:
-
- WKYMVMAMIDE TRIFLUOROACETATE
- WKYMVM
- H-Trp-Lys-Tyr-Met-Val-D-Met-NH2
- H-TRP-LYS-TYR-MET-VAL-D-MET-NH2 TRIFLUOROACETATE
- M.W. 856.11 C41H61N9O7S2
- Tryptophanyl-lysinyl-tyrosinyl-methionyl-valinyl-D-methionine
- Trp-Lys-Tyr-Met-Val-D-Met
- WKYMVMaMide, W-Peptide
- CAS:
- 187986-17-0
- MF:
- C41H61N9O7S2
- MW:
- 856.11
- Product Categories:
-
- N-Formyl Peptide receptor
- Mol File:
- 187986-17-0.mol
More
Less
FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM Chemical Properties
- Boiling point:
- 1269.6±65.0 °C(Predicted)
- Density
- 1.268±0.06 g/cm3(Predicted)
- storage temp.
- -20°C
- solubility
- H2O: >2mg/mL
- form
- powder
- pka
- 9.82±0.15(Predicted)
- color
- white to off-white
- Water Solubility
- Soluble to 2 mg/ml in water
- Sequence
- Trp-Lys-Tyr-Met-Val-{d-Met}-NH2
More
Less
FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVM Usage And Synthesis
Uses
WKYMVm is a lipoxin A4 receptor and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2.
in vivo
WKYMVm (4 mg/kg; Intraperitoneal injection; 3 times; 24 h interval) has a protective effect in rat spinal cord injury model[3].
WKYMVm (2.5 mg/kg; Intraperitoneal injection; 4 days) can alleviate hyperoxy-induced lung injury in neonatal mice[4].
WKYMVm (8 mg/kg; Subcutaneous injection; Once every two days; 2-5 weeks) improves obesity in high-fat fed mouse models[5].
| Animal Model: | Adult female Sprague-Dawley rats (200-220 g) with spinal cord injury[3] |
| Dosage: | 4 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); 3 times with 24 hours intervals |
| Result: | Reduce structural disorders and neuronal loss. Reduced the phosphorylation of ERK1/2 and NF-κB p65 but not p38. |
| Animal Model: | Normoxia or hyperoxic treated newborn mouse pups of C57/BL6[4] |
| Dosage: | 2.5 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); daily from postnatal day (P) 5 to P8. |
| Result: | Significantly attenuated hyperoxia-induced lung inflammation, as evidenced by increased inflammatory cytokines, neutrophils, and alveolar macrophages, and resultant lung injuries, which included impaired alveolarization and angiogenesis, an increased number of apoptotic cells, and reduced levels of growth factors in vivo, such as vascular endothelial growth factor and hepatocyte growth factor. |
| Animal Model: | High fat diet treated male wild-type C57BL/6N mice aged 8 weeks old (21?±?2?g)[5] |
| Dosage: | 8?mg/kg |
| Administration: | Subcutaneous injection (i.h.); once every 2?days; 2 or 5 weeks |
| Result: | Significantly attenuated body weight gain, food intake and increased insulin sensitivity. Markedly ameliorated HFD-induced hepatic steatosis and adipose tissue hypertrophy. Improved lipid metabolism in adipose tissue. Improved leptin signalling in the hypothalamus. |
storage
Store at -20°C
FORMYL PEPTIDE RECEPTOR-LIKE 1 AGONIST, WKYMVMSupplier
3B Pharmachem (Wuhan) International Co.,Ltd.
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
GL Biochem (Shanghai) Ltd
- Tel
- 21-61263452 13641803416
- ymbetter@glbiochem.com
Shanghai Hanhong Scientific Co.,Ltd.
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
Chemsky（shanghai）International Co.,Ltd.
- Tel
- 021-50135380
- shchemsky@sina.com
Wuxi Zhongkun Biochemical Technology Co., Ltd.
- Tel
- 0510-85629785 18013409632
- sales@reading-chemicals.com